Neutrophil gelatinase-associated lipocalin (NGAL) as a prognostic marker in chronic myeloid Leukemia: an observational study
DOI:
https://doi.org/10.18203/2320-6012.ijrms20175446Keywords:
Chronic myeloid leukemia, Imatinib, RemissionAbstract
Background: Neutrophil gelatinase-associated lipocalin (NGAL) is a protein which is associated with various inflammatory conditions affecting human tissues, such as those in the respiratory, gastro-enteric and urinary tracts, with a marked increase in the local and systemic expression. Different experimental evidences reveal that NGAL is required for the induction and pathogenesis of chronic myeloid leukemia (CML).
Methods: The present study was conducted in department of Biochemistry in a tertiary care institute of Haryana. 30 cases of CML were included in the study. It was a hospital based observational study which was conducted for one-year duration. Apart from routine biochemical investigations, serum NGAL estimation was done before the initiation of therapy and after 3 months of therapy.
Results: The median age at presentation was 39 years. Male to female ratio was 1.3:1. Weight loss was the most common presentation of patients (53.3%). More than half of the cases occurred in age group of 21-40 years. Serum NGAL was significantly higher in CML patients (358.47±125.65) before treatment as compared to serum NGAL value after treatment (85.03±62.77). In patients who achieved hematological remission, mean serum NGAL levels (62.46 ng/ml±23.72) were statistically lower than mean serum NGAL values in patients who did not achieve remission (231.75 ng/ml±16.7).
Conclusions: The present study concluded that serum NGAL levels can be used as diagnostic and prognostic marker in CML.
References
Wetzler M, Bloomfeild CD. Acute and chronic leukemia. In: Fauci AS, Kasper DL, Braunwald E, Hauser SL, Longo DL, Jameson JL, editors. Harrison’s Principle of Internal Medicine, 17th ed.New York:McGraw Hill;2008:677-86.
National Cancer Registry Programme. Two-year report of the population based cancer registries 1999-2000. New Delhi: Indian Council of Medical Research;2005.
Deininger MW, Goldman JM, Melo JV. The molecular biology of chronic myeloid leukemia. Blood. 2000;96:3343-56.
Manero GG, Faderl S, O’Brien S, Cortes J, Talpaz M, Kantarjian HM. Chronic myelogenous leukemia: A review and update of therapeutic strategies. Cancer. 2003;98:437-57.
Aziz Z, Iqbal J, Akram M, Saeed S. Treatment of chronic myeloid leukemia in the Imatinib Era. Cancer. 2007;109:1138-45.
Xu S, Venge P. Lipocalins as biochemical markers of disease. Biochim Biophys Acta. 2000;1482:298-307.
Bolignano D, Donato V, Coppolino G, Campo S, Buemi A, Lacquaniti Aet al.Neutrophil Gelatinase-Associated Lipocalin (NGAL) as a marker of kidney damage. Am J Kidney Dis. 2008;52:595-609.
Gwira JA, Wei F, Ishibe S, Ueland JM, Barasch J, Cantley LG. Expression of neutrophil gelatinase -associated lipocalin regulates epithelial morphogenesis in vitro. J Biol Chem. 2005;280:7875-82.
Bratt T. Lipocalins and cancer. Biochim Biophys Acta. 2000;1482:318-26.
Devireddy LR, Gazin C, Zhu X, Green MR. A cell-surface receptor for lipocalin 24p3 selectively mediates apoptosis and iron uptake. Cell. 2005;123:1293-1305.
Arlinghaus R, Leng X. Requirement of lipocalin 2 for chronic myeloid leukemia. Leuk Lymphoma. 2008;49:600-3.
Leng X, Lin H, Ding T, Wang Y, Wu Y, Klumpp S et al. Lipocalin 2 is required for BCRABL-induced tumorigenesis. Oncogene. 2008;27:6110-19.
Hu L, Hittelman W, Lu T, Ji P, Arlinghaus R, Shmulevich I et al. NGAL decreases E-cadherin-mediated cell-cell adhesion and increases cell motility and invasion through Rac1 in colon carcinoma cells. Lab Invest. 2009;89:531-48.
Lin H, Monaco G, Sun T, Ling X, Stephens C, Xie S et al. Bcr-Abl mediated suppression of normal hematopoiesis in leukemia. Oncogene. 2005;24:3246-56.
Villalva C, Sorel N, Bonnet ML, Guilhot J, Mayeur-Rousse C, Guilhot F, et al. Neutrophil gelatinase-associated lipocalin expression in chronic myeloid leukemia. Leuk Lymphoma. 2008;49:984-88.
Owen HC, Roberts SJ, Ahmed SF, Farquharson C. Dexamethasone-induced expression of the glucocorticoid response gene lipocalin 2 in chondrocytes. Am J Physiol Endocrinol Metab. 2008;294:E1023-34.
Golde DW, Champlin RE. Chronic myelogenous leukemia: Recent advances. Blood. 1985;65:1039-41.
Sawyers CL. Chronic myeloid leukemia. N Eng J Med. 1999;340:1330-40.
Kantarjian HM, Deisseroth A, Kurzrock R, Estrov Z, Talpaz M. Chronic myelogenous leukemia: A concise update. Blood. 1993;82:691-703.
Druker BJ, Tamura S, Buchdunger E, Ohno S, Segal GM, Fanning S et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med. 1996;2:561-66.
Kantarjian HM, Cortes JE, O’BrienS. Imatinib mesylate therapy in newly diagnosed patients with Philadelphia chromosome-positive chronic myelogenous leukemia: high incidence of early complete and major cytogenetic responses. Blood. 2003;101:97-100.
Hanai J, Mammoto T, Seth P, Mori K, Karumanchi SA, Barasch J et al. Lipocalin 2 diminishes invasiveness and metastasis of Ras-transformed cells. J Biol Chem. 2005;280:3641-47.
